Home
Search
Study Topics
Glossary
|
|
|
|
|
Tracking Information | |
---|---|
First Received Date † | March 31, 2001 |
Last Updated Date | October 1, 2007 |
Start Date † | February 2001 |
Current Primary Outcome Measures † | |
Original Primary Outcome Measures † | |
Change History | Complete list of historical versions of study NCT00013897 on ClinicalTrials.gov Archive Site |
Current Secondary Outcome Measures † | |
Original Secondary Outcome Measures † | |
Descriptive Information | |
Brief Title † | A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine |
Official Title † | A Phase III Study Comparing the Antiviral Efficacy and Safety of BMS-232632 With Efavirenz; Each in Combination With Fixed Dose Zidovudine-Lamivudine |
Brief Summary | The purpose of this study is to compare the effectiveness of treatment with BMS-232632 to that of efavirenz (EFV) when both are used with zidovudine (ZDV) and lamivudine (3TC). |
Detailed Description | This is a multinational, 2-arm study. Patients in 1 arm receive BMS-232632 plus EFV placebo capsules. Patients in the other arm receive EFV plus BMS-232632 placebo. Both arms also receive a fixed dose of ZDV-3TC. |
Study Phase | Phase III |
Study Type † | Interventional |
Study Design † | Treatment, Double-Blind |
Condition † | HIV Infections |
Intervention † |
|
Study Arms / Comparison Groups | |
Publications * | |
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|
Recruitment Information | |
Recruitment Status † | Completed |
Enrollment † | |
Completion Date | |
Primary Completion Date | |
Eligibility Criteria † | Inclusion Criteria Patients may be eligible for this study if they:
Exclusion Criteria Patients will not be eligible for this study if they:
|
Gender | Both |
Ages | 16 Years and older |
Accepts Healthy Volunteers | No |
Contacts †† | |
Location Countries † | United States, Austria, Belgium, Canada, Chile, Costa Rica, France, Germany, Guatemala, Hungary, Israel, Italy, Malaysia, Panama, Peru, Portugal, Puerto Rico, Russian Federation, South Africa, Spain, Switzerland, Thailand, United Kingdom, Venezuela |
Expanded Access Status | |
Administrative Information | |
NCT ID † | NCT00013897 |
Responsible Party | |
Secondary IDs †† | AI424-034 |
Study Sponsor † | Bristol-Myers Squibb |
Collaborators †† | |
Investigators † | |
Information Provided By | Bristol-Myers Squibb |
Verification Date | October 2007 |
† Required WHO trial registration data element. †† WHO trial registration data element that is required only if it exists. |